is the third largest pharmaceutical company
and a top 16 pharmaceutical company in the world. The company has over 30,000 employees worldwide and achieved $9.7 billion USD in revenue during the 2009 fiscal year. Its headquarter is based in Tokyo
and the independent subsidiaries Plexxikon
and U3 Pharma
are located in Berkeley
, CA and Munich
Daiichi Sankyo was established in 2005 through the merger of and , which were century-old pharmaceutical companies
based in Japan
In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs
unit of Astellas Pharma
On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian
generic drug maker Ranbaxy
, with a deal valued at about $4.6 billion.
In June 2008, Daiichi Sankyo acquired U3 Pharma
, which would contribute a therapeutic anti-HER3
antibody to the company's anticancer portfolio.
On April 4, 2011 Daiichi Sankyo completed the acquisition of Plexxikon, a Berkley CA-based pharmaceutical start-up company for $805 and an additional $130 in milestone payments, pending on the success of Vemurafenib (Plexxikon’s lead program) an oral, novel drug that targets the oncogenic BRAF mutation present in about half of melanoma cancers and about eight percent of all solid tumors. Daiichi Sankyo is retaining US co-promotion right of the (GSK licensed) drug.
Products of Daiichi......